Consumer Drug Returns Regulatory Challenges, Proposed Solutions Joanie Burns Wisconsin Department of Natural Resources Mary Hendrickson,RPh,MBA Capital.

Slides:

Advertisements

Similar presentations

Our role in the U.S. pharmaceutical supply chain:

Advertisements

DRUG (R X & OTC) DISPOSAL PROGRAMS Solid Waste Management Coordinating Board 5/30/2012.

Waste Management and Stewardship Thomas J. Lauro, P.E. Commissioner, Department of Environmental Facilities Susan Gerry Senior Assistant to the County.

Regulations & Reality Long Term Care & DEA’s New Rule for Controlled Substances June 26, 2013 NAHHMA Conference Mindy Collins, Local Source Control Specialist.

“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.

PTCB Review 3 Calculations Federal Law 1. How many 30-mg tablets of codeine sulfate should be used in preparing the following Rx? Rx: Codeine sulfate15.

Lessons Learned from the Reverse Distribution Industry and Implications for National Consumer Take-Back Programs 5th Annual Maine Benzodiazepine Study.

Unused Patient Medication Disposal. 2 Concerns About Pharmaceutical Disposal Pharmaceuticals have been found in surface and ground sources of drinking.

Keeping Our Sewers Pharmaceutical-Free Thru Public Education, Outreach and Resource Coordination Susanna Littell Section Manager, Environmental Compliance.

NYS Department of Environmental Conservation Reducing Pharmaceuticals in Water: DEC’s Proactive Approach to Household, Institutional, and Manufacturing.

Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.

1.  Part I: Academic Labs Rule (Subpart K) › Finalized in 2008  Part II: HW Pharmaceuticals Proposed Rule › Under development  Questions 2.

Highlights and Lessons Learned from the 2006 SF Bay Area’s Safe Medicine Disposal Days sponsored by the Bay Area Pollution Prevention Group Karin D. North.

Reverse Distribution & Designing a National Consumer Rx Returns Program October 23, 2006 Mary Hendrickson,RPh,MBA Director of Quality & Regulatory Affairs.

1 Promoting Safe Medicine With Track and Trace Systems SRC Technologies, Inc.

Inmar CLS MedTurn Pharmaceutical Symposium October 19-20, 2009 Rodney Bias, VP Regulatory.

The Dilemma of Waste Pharmaceuticals Ann Pistell Maine Department of Environmental Protection (207)

Regulatory Body MODIFIED Day 8 – Lecture 3.

PH:ARM (Pharmaceuticals from Households: A Return Mechanism) Washington State’s Medicine Return Cheri Grasso King County Hazardous Waste Management 4 th.

Best Management Practices for Pharmaceutical Disposal - History Veterinarians are minimal contributors to drug waste into our nation’s waterways Fall 2008:

Prescription Drug Take Back Program -. How do you dispose of your unwanted medication? Most common disposal practices: Flushing down the toilet Throwing.

McKean County, PA Unwanted Medication Collection Program Bradford Regional Medical Center Bradford, PA, McKean County Saturday, May 16, 2009, 8 to Noon.

The Drug Management Cycle – Distribution

The TCEQ's Pharmaceutical Disposal Study (S.B. 1757)

Secure and Responsible Drug Disposal Act of 2010 Takes Effect 10/9/2014 DEA’s goal in implementing the Act is to expand the options available to safely.

Controlled Substance Collection and Disposal An Opportunity for New Partnerships Under the New Drug Enforcement Agency (DEA) Regulations.

Development of a Road Map to Controlled Substance Diversion Prevention Rene Cronquist, RN, J.D. Director of Practice and Policy Minnesota Board of Nursing.

PH:ARM – Pharmaceuticals from Households: A Return Mechanism Controlled Substance Act: Regulatory Barriers for A Pilot Waste Management Program April 18,

Pharmaceutical Waste Take Back in Wisconsin Steve Brachman Waste Reduction Specialist UW-Extension Solid & Hazardous Waste Education Center.

Overview of Drug Return Programs Sego Jackson, Snohomish County WA and Northwest Product Stewardship Council May 18, 2006.

Managing Pharmaceutical Reverse Logistics

Name Secure Medicine Return: PH:ARM Pilot in Washington State Shirley Reitz, Pharm.D., BCPS Associate Director, Pharmacy Clinical Services Group Health.

Pharmacists’ Perspective on Unwanted/Waste Pharmaceuticals PSI: Pharmaceuticals National Dialogue Sacramento, CA June 19, 2008 Shirley Reitz, Pharm.D.,

PHARMACEUTICAL TAKE-BACK PROGRAM MODELS International programs U.S. programs Program attributes Public need Essential program elements.

Deriving Value from Your Pharma Take-Back Program Leo Raudys Vice President, Program Development.

Pharmaceuticals from Households: A Return Mechanism.

© Product Stewardship Institute, Inc. May 2008 PSI National Dialogue on Medical Sharps Boston, MA May 21-22, 2008.

Platinum Thank you to our sponsors! Gold National Association of Clean Water AgenciesWaste Treatment Division, King County, WA San Francisco, CA – Department.

A Reverse Distribution Perspective Of The Issues Of Pharmaceutical Collection The 1st National Pharmaceutical Product Stewardship Dialogue Meeting June.

NYS Department of Environmental Conservation Reducing Pharmaceuticals in our Waters: A DEC Update and Appeal for your Input Scott Stoner, Chief, Standards.

Presentation #17 Expired Drugs/Devices Verification of the Drug to be Discarded §Compare expiration dates listed in the Drug Inventory Log with actual.

Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.

LECTURE FOR ASSIGNMENT 1 AND 2

Management of Unused Patient Dispensed Medications Annual Conference September 17, 2015.

PSI National Dialogue on Waste Pharmaceuticals Product Stewardship Forum June 2, 2009.

California Integrated Waste Management Board 1 Consideration of Model Programs and Procedures for the Collection and Proper Disposal of Pharmaceutical.

Introduction Everyone working in pharmacy maintains inventory stock Stock depleted: replacement inventories ordered Task delegated to specific person.

NYS Department of Environmental Conservation Pharmaceutical Contaminants DEC Actions to Reduce Exposure Presentation to the Watershed Science and Technical.

Preventing Prescription Drug Abuse Northern Michigan Regional Entity.

6th Annual Prescription Drug Abuse Symposium In the Trenches - A Community Approach In the Trenches - A Community Approach Medicine Waste Disposal: Take.

PROPER DISPOSAL OF UNWANTED MEDICATIONS “THE DISPOSAL PROPOSAL” Patti Darbishire, PharmD Clinical Associate Professor, Pharmacy Practice.

Maryam Noureldin and Sumaya Bahrami, PharmD Candidates, Anne Packard, PharmD Student A. Carmine Colavecchia, PharmD, MS, BCPS and Patricia L. Darbishire,

Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.

SFEnvironment.org SF’s Safe Medicine Disposal Program.

Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Pennsylvania's Prescription Drug Monitoring Program (PDMP) May 17, 2016.

Deriving Value from Your Pharma Take-Back Program

Inventory Management Chapter 13.

Medication Administration

Quick Regulatory Guide

The importance of drug take-back programs: protecting our health and environment [TEMPLATE PRESENTATION] prepared by the product stewardship institute.

Safe Disposal of Prescription Medications

The importance of drug take-back programs: protecting our health and environment [TEMPLATE PRESENTATION] prepared by the product stewardship institute.

Executive Director Teleosis Institute (510)

Controlled Substances

Using Data to Combat the Opioid Overdose Crisis

Controlled Substances

Compounded Drugs and Lack of Premarket FDA-Approval

Controlled Substances

PSI National Dialogue on Medical Sharps

OSU Controlled Substances Training Module for Researchers

Presentation transcript:

Consumer Drug Returns Regulatory Challenges, Proposed Solutions Joanie Burns Wisconsin Department of Natural Resources Mary Hendrickson,RPh,MBA Capital Returns, Inc.

Agenda Review of drug distribution Regulatory challenges Wisconsin initiatives Proposed solutions

Debit memo information Reporting Process Overview Distribution Wholesaler returns Pharmacy returns Distribution Direct accounts only Hospitals Independents Chains ManufacturersWholesalers Retail/Institutional Pharmacies, LTC, Other indirect customer, etc. Reverse Distributors Incinerators Creditable product Waste

Process Overview Distribution MailOrderIndependentChains Manufacturers Wholesalers Retail Pharmacies Reverse Distributors Incinerators Returns Data Waste Distribution Pharmacy Returns Consumer/PatientsSchools Long Term Care Facilities Distribution

Regulatory challenges with consumer returns Overall goal of the controlled substances act is to provide a closed distribution system. A DEA concern: diversion already occurs to some extent in spite of all precautions with the closed loop system. Goal: provide an environmentally safe system to return unused consumer pharmaceutical products while minimizing diversion, abuse, accidental poisonings and overdosing.

Patients and other “end users” Current best case scenario: material brought to a collection event or sent for other safe, environmentally sound management Considerations: Safety/diversion Patient confidentiality/HIPPA Staffing and participants Real world: no collection event or patient leaves it behind Nursing homes/other non-hospital healthcare facility Home (patient dies) School Pharmacy

Patients and other “end users” What are the issues? Nursing homes/other non-hospital healthcare facilities Flush policies Household or business? Waste or product? Home (patient dies) Family members Coroners and medical examiners School Pharmacy Waste or product?

Collection events Easiest scenario: all material sent for hazardous waste (HW) incineration Real world: non-controlled substances sent for HW incineration; controlled substances taken into possession by law enforcement What is law enforcement doing with it?

Controlled substances and law enforcement What are the issues? Public Safety versus Environmental Considerations

Controlled substances and law enforcement What are the issues? WI law enforcement survey Waste Management 101 Logistics Costs Schedule I controlled substances

Management of Controlled Substances Wisconsin’s “temporary fixes” Nursing homes/other non-hospital healthcare facilities DHFS guidance and “enforcement discretion” DNR/DHFS regulatory consensus Schools, coroners and medical examiners Outreach and education Practical application of law Law enforcement In-state infrastructure Dialogue

A proposed solution: Acceptance from non-registrants Potential ways this could work: In-pharmacy return “Hands off” collection e.g., secure box Kept separate from products/creditable materials generated by the pharmacy DEA registered waste companies Direct from collection events From law enforcement agencies Reverse distributors

A proposed solution: reverse distributors Reverse Distribution centralizes outdated drugs into a finite numbers of locations. Core competency is receipt, documentation, and proper disposal of outdated drugs. Outsourcing by pharmacies for processing outdated drugs: near 100%. Limited number of reverse distributor DEA registrants. Precedent with DEA already exists in the management of recalled controlled substances.

Proposed Logistics: Unused pharmaceutical product sent back to a reverse distributor. Mail back program Distribution MailOrderIndependentChains ManufacturersWholesalers Retail Pharmacies Reverse Distributors Incinerators Returns Data Waste Distribution Patients, LTC Facilities, Schools Dispense Adapted by permission from Capital Returns, Inc. Pharmacy Returns Returns

The benefits of a reverse distributor solution: Relevant data is recorded and retained by the RD as required by the CSA. Includes drug name, dosage, quantity, etc. All product sent for incineration Controlled substances sent through routine witness incineration. Unwanted, unused medications are removed from the “wrong” hands: accidental poisonings, overdose, etc. Data obtained could prove to be very beneficial: manufacturers, insurance providers.

Summary DEA closed distribution system leaves out the consumer and the millions of pharmaceuticals they never end up using. Current system (s) are not sustainable Requirements are contributing to poor environmental practices Workable alternatives exist